Sermorelin (GRF 1-29): A Research Overview

Sermorelin holds a distinctive place among growth hormone secretagogues: it is the most “native” of the GHRH analogs and has the strongest regulatory history of any compound in this class — it was once an FDA-approved drug. It acts on the GHRH receptor, the same pathway as tesamorelin and CJC-1295, and it is the closest synthetic stand-in for the body’s own GHRH signal. That combination of genuine clinical pedigree and short, physiological action is what makes it a reference point for the whole secretagogue field.

This overview summarizes what the published literature reports about Sermorelin — its structure, mechanism, evidence, regulatory history, and current status. It describes findings as they appeared in their study systems. It is not dosing guidance, medical advice, or a recommendation for use.

What Sermorelin Is

Sermorelin (sermorelin acetate; also written GRF 1-29 or GHRH 1-29; CAS 86168-78-7) is a synthetic peptide corresponding to the first 29 amino acids of human growth hormone-releasing hormone. Although native GHRH is 44 amino acids long, the biological activity resides in that first 29-residue region, so the truncated fragment retains essentially full GHRH activity (Sermorelin identity (GRF 1-29), reference entry). Its half-life is short — on the order of 10–12 minutes — producing a sharp, brief GH pulse.

Mechanism — The GHRH Receptor

Sermorelin binds the GHRH receptor (GHRHR) on pituitary somatotroph cells, stimulating the synthesis and release of the body’s own growth hormone, which in turn drives hepatic IGF-1 production. This is a true secretagogue action — it prompts the pituitary to make and release its own GH, rather than supplying external GH — and because it works through the natural pathway, the response remains subject to the body’s normal regulatory feedback (including somatostatin) (GHRH-receptor mechanism (Ishida et al. GHS review)).

This places Sermorelin in the same mechanistic family as tesamorelin and CJC-1295, all GHRH receptor agonists, and distinct from the ghrelin receptor (GHS-R1a) secretagogues such as ipamorelin and the GHRPs. Sermorelin’s short half-life makes it the most pulsatile and physiologically native of the GHRH analogs; CJC-1295’s engineering extends that signal, while ipamorelin adds a separate, synergistic pathway (GHRH- vs ghrelin-receptor pathways (Ishida et al. review)).

Regulatory History — A Former FDA-Approved Drug

Sermorelin’s defining distinction in this library is that it was, for a time, an approved drug. It received FDA approval (brand name Geref) for use as a diagnostic agent to assess growth hormone secretion in evaluating growth hormone deficiency, and it was also used in pediatric GH-deficiency contexts (Geref approval and diagnostic use, reference entry). Its U.S. commercial production was subsequently discontinued — reportedly for business rather than safety reasons — so its current U.S. status is “discontinued” rather than actively marketed as an approved product (Geref discontinued (US) — drug record). This history is meaningfully different from that of compounds that were never approved at all, and worth stating accurately: a real prior approval for a diagnostic indication, now discontinued.

The Evidence Base

As a formerly approved drug and a long-studied GHRH analog, Sermorelin has substantial human clinical literature, including its diagnostic use and reviews of GHRH-analog pharmacology in growth hormone deficiency (Ishida et al. GHS history and clinical development review). One practical, evidence-based point worth noting: Sermorelin is a peptide and is broken down in the digestive tract, so oral or sublingual formulations are not supported by the peer-reviewed literature as equivalent to injection.

The honest limit on contemporary “wellness” and anti-aging uses: the robust clinical evidence concerns its approved diagnostic role and GH-deficiency contexts, not large long-term trials for body-composition or longevity optimization in healthy adults. Its approval pedigree is real but specific.

• Sermorelin has genuine human clinical data, anchored in its former approved diagnostic use.
• Oral/sublingual forms are not supported as equivalent to injection in the peer-reviewed literature.
• Long-term anti-aging/body-composition use in healthy adults is not backed by large controlled trials.

Current Regulatory and Anti-Doping Status

The status below reflects mid-2026 and may change; verify before relying on it. The originally approved Sermorelin product (Geref) is discontinued in the United States; Sermorelin is no longer marketed as an actively approved finished drug, though it has been dispensed through compounding pharmacies. Material sold by research suppliers is for laboratory use only and, by its labeling, not for human consumption. As a growth hormone secretagogue, Sermorelin is prohibited in sport by the World Anti-Doping Agency (Category S2). As with all GH-axis compounds, GH/IGF-1 elevation is mitogenic, and the general caution against use with active or prior malignancy applies.

Why Sermorelin Draws Research Interest

Sermorelin is the reference GHRH analog — the most physiologically native secretagogue, with a genuine clinical and regulatory track record, useful for modeling normal pulsatile GH secretion and as the baseline against which engineered analogs (CJC-1295) and ghrelin-pathway agents (ipamorelin) are compared. The accurate framing is a well-characterized GHRH analog with a real former FDA diagnostic approval (now discontinued), solid clinical pedigree for that role, no current marketed approval, and the standard secretagogue safety and anti-doping considerations.

For deeper reading, the cited literature is the best starting point, and the related overviews of CJC-1295, Tesamorelin, Ipamorelin, GHRP-2, and GHRP-6 complete the growth-hormone-secretagogue picture. The wider class is collected in our peptide research library.